\n
EDQM<\/p>\n
Issuing body, not a national regulator<\/p>\n<\/div>\n<\/td>\n
\n\n 5 years<\/p>\n Renewal point after original issue date<\/p>\n<\/div>\n<\/td>\n<\/tr>\n \n\n\n 171596-29-5<\/p>\n Tadalafil CAS number (C22H19N3O4)<\/p>\n<\/div>\n<\/td>\n \n\n Ph. Eur.<\/p>\n Tadalafil is an established monograph substance<\/p>\n<\/div>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n Ask a tadalafil API supplier for credentials and a CEP will usually be among the first things offered, often as a scanned PDF attached to the quotation. It looks authoritative, it carries a European regulator’s name, and it is frequently presented to American buyers as general proof of quality. That last framing is where the trouble starts.<\/p>\n A Certificate of Suitability answers one narrow, specific question, and it answers it for one regulatory system. This guide explains what a CEP for tadalafil actually certifies, when a US-facing buyer genuinely needs one, and how to check that the certificate in your inbox is still valid.<\/p>\n What is a CEP for tadalafil API?<\/h2>\nCEP stands for Certificate of Suitability to the monographs of the European Pharmacopoeia. It is issued by the European Directorate for the Quality of Medicines and HealthCare (EDQM), a body of the Council of Europe, under the certification procedure established by Resolution AP-CSP (07) 1. [Source: EDQM, Certification Policy Documents and Guidelines]<\/p>\n The certificate confirms that a specific manufacturer’s substance, made by a specific route at a specific site, can be adequately controlled by the relevant Ph. Eur. monograph, with any additional tests the assessment found necessary. Tadalafil qualifies for the procedure because it is an established active substance described in the European Pharmacopoeia. [Source: HPRA Public Assessment Report, tadalafil film-coated tablets, 2024]<\/p>\n Practically, the CEP lets a European marketing authorisation applicant reference the certificate in the quality section of its dossier instead of submitting the API manufacturer’s confidential chemistry itself. It is a filing shortcut backed by an EDQM assessment, which is a genuinely useful thing. It is not a quality medal.<\/p>\n ![\"What](\"https:\/\/tadalafil-seller.com\/blog\/wp-content\/uploads\/2026\/09\/ChatGPT-Image-Sep-4-2026-11_59_42-PM-1024x576.png\") <\/p>\n
Does a US buyer need a CEP-certified tadalafil supplier?<\/h2>\n\n Answered plainly<\/p>\n For a US filing, no. A CEP is not recognised by the FDA as a substitute for the chemistry, manufacturing and controls support a US application requires. An ANDA or NDA referencing an outside API source normally relies on a Type II Drug Master File referenced under a Letter of Authorization. A supplier offering a CEP in place of a DMF has not met a US requirement.<\/p>\n<\/div>\n That said, there are four situations where a US-based buyer should actively want a CEP on the table:<\/p>\n \n- Dual-market products.<\/strong> If the same tadalafil tablet is going to the US and the EU or UK, you need US-appropriate support and European support from the same API source. Sourcing a supplier who holds both avoids requalifying later.<\/li>\n
- Ex-US markets that recognise the CEP.<\/strong> A number of regulators outside Europe accept or give weight to a CEP. If your distribution map extends beyond North America, it can save a filing.<\/li>\n
- Corroborating evidence.<\/strong> A current CEP tells you an independent European assessor has looked at the manufacturer’s route and specification. That is not a US credential, but it is not nothing when you are comparing shortlisted sites.<\/li>\n
- Supplier maturity signal.<\/strong> Holding and maintaining a CEP means the manufacturer runs a regulatory affairs function capable of tracking monograph revisions and filing variations. Undocumented traders do not.<\/li>\n<\/ul>\n
What none of that supports is treating a CEP as a general-purpose stamp of approval or as a reason to skip US-specific qualification. See our companion guide on USDMF tadalafil API manufacturers<\/a> for the US side of the same shortlist.<\/p>\nCEP vs USDMF vs ASMF vs GMP certificate<\/h2>\n \n\n\n| Document<\/th>\n | Issued by<\/th>\n | Supports filings in<\/th>\n | What it confirms<\/th>\n<\/tr>\n<\/thead>\n | \n\nCEP<\/strong><\/td>\n| EDQM<\/td>\n | Europe, plus recognising markets<\/td>\n | The substance from a named site and route is adequately controlled by the Ph. Eur. monograph<\/td>\n<\/tr>\n | \nUSDMF (Type II)<\/strong><\/td>\n| Filed with US FDA<\/td>\n | United States<\/td>\n | A confidential CMC dossier is on file and can be referenced under an LOA. Not an approval<\/td>\n<\/tr>\n | \nASMF<\/strong><\/td>\n| Submitted to EU national or central authorities<\/td>\n | Europe<\/td>\n | The European alternative to a CEP: open and restricted parts assessed within each application<\/td>\n<\/tr>\n | \nGMP certificate<\/strong><\/td>\n| An inspectorate (EU authority, WHO-GMP, national)<\/td>\n | Varies by issuer<\/td>\n | A named site passed inspection on a date, for a defined scope. Separate from any dossier<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\nWhat a CEP does not cover<\/h2>\n\n \n- It is not a GMP certificate.<\/strong> EDQM certification and GMP inspection are separate processes with separate outcomes.<\/li>\n
- It does not cover the finished dosage form.<\/strong> A CEP applies to the active substance, not to your tablet.<\/li>\n
- It does not certify a batch.<\/strong> Batch conformity is evidenced by the Certificate of Analysis, and the two documents answer different questions.<\/li>\n
- It is site-specific and route-specific.<\/strong> Material made at a second site, or by an alternate route, is outside the certificate’s scope even when the company name is the same.<\/li>\n
- It does not survive neglect.<\/strong> A CEP can be suspended or cancelled, and EDQM maintains a policy governing exactly that. [Source: EDQM, Suspension or cancellation of a certificate of suitability, PA\/PH\/CEP (08) 17]<\/li>\n<\/ul>\n<\/div>\n
How to verify a tadalafil CEP in five steps<\/h2>\n\n\n\n\n01<\/div>\n<\/td>\n \n Get the certificate reference and holder name in writing<\/p>\n Every CEP carries a unique reference including a revision indicator. Ask for the full reference and the exact legal name of the holder, not the trading name on the invoice.<\/p>\n<\/td>\n<\/tr>\n | \n\n02<\/div>\n<\/td>\n \n Look it up in EDQM’s certification database, not in the PDF<\/p>\n EDQM publishes a searchable database of granted certificates. A PDF proves a certificate existed on the day it was scanned. The database tells you its status today.<\/p>\n<\/td>\n<\/tr>\n | \n\n03<\/div>\n<\/td>\n \n Check the revision number and the renewal position<\/p>\n A CEP must be renewed once, five years after the issue date of the original certificate, for it to remain valid, regardless of any revisions in the interim. Confirm where the certificate sits against that clock. [Source: EDQM, Notifications, Revisions, Renewals and Sister Files]<\/p>\n<\/td>\n<\/tr>\n | \n\n04<\/div>\n<\/td>\n \n Match the site and route to what is being quoted<\/p>\n Confirm in writing that the tadalafil in the quotation is made at the manufacturing site named on the certificate, by the route the certificate covers. Sister files, second sites and toll arrangements all need explicit clarification.<\/p>\n<\/td>\n<\/tr>\n | \n\n05<\/div>\n<\/td>\n \n Ask about monograph currency<\/p>\n Ask when the holder last updated the application against a revised Ph. Eur. monograph. EDQM notes that CEP holders retain this obligation whether or not EDQM has contacted them, and that failing to update may challenge the validity of the granted certificate. [Source: EDQM, Ph. Eur. implementation notifications for CEP holders]<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n Monograph revisions: the maintenance question buyers forget<\/h2>\nThe European Pharmacopoeia is revised on a rolling schedule, and each issue brings implementation dates for revised monographs. EDQM classifies those updates into two categories, Case A and Case B, which determine what a holder must submit and by when. [Source: EDQM, Implementation of the European Pharmacopoeia, notifications for CEP holders]<\/p>\n Under Directive 2001\/83\/EC as amended, it is the manufacturer’s responsibility to comply with the current version of a monograph and to update the specification when a revised one is issued. EDQM contacts affected holders as a courtesy, but the obligation sits with the holder regardless. [Source: EDQM, notifications for CEP holders]<\/p>\n EDQM has also revised its guideline on requirements for revision and renewal of CEPs to align with updated EU variations legislation, including Commission Delegated Regulation (EU) 2024\/1701. A supplier whose regulatory team cannot describe how it tracks this is a supplier whose certificate may quietly go stale. [Source: EDQM, revised guideline PA\/PH\/CEP (04) 02]<\/p>\n ![\"Monograph](\"https:\/\/tadalafil-seller.com\/blog\/wp-content\/uploads\/2026\/09\/ChatGPT-Image-Sep-5-2026-12_02_41-AM-1024x576.png\") <\/p>\n
Red flags in CEP claims<\/h2>\n\n Escalate to QA or RA before proceeding<\/p>\n \n- “CEP approved by the EMA” or “EU approved API”. EDQM issues CEPs; the EMA does not, and neither approves an API in isolation<\/li>\n
- A CEP offered as a substitute for US regulatory support<\/li>\n
- A scanned certificate with the reference number cropped, blurred or redacted<\/li>\n
- A holder name that differs from the quoting entity with no explanation of the relationship<\/li>\n
- An issue date more than five years old with no evidence of renewal<\/li>\n
- No answer to the question of which Ph. Eur. issue the application is currently aligned to<\/li>\n
- A certificate covering a site other than the one that will make your material<\/li>\n<\/ul>\n<\/div>\n
Clinical context: what the API becomes<\/h2>\nTadalafil is a phosphodiesterase type 5 (PDE5) inhibitor, approved in finished dosage form for erectile dysfunction, the signs and symptoms of benign prostatic hyperplasia, and pulmonary arterial hypertension, marketed as Cialis and Adcirca and as generics. Buyers qualifying an API source do not prescribe, but the finished product’s profile is what sets the impurity, uniformity and stability expectations placed on the drug substance. [Source: FDA Prescribing Information, Cialis and Adcirca; EMA Summary of Product Characteristics, Cialis]<\/p>\n \n\n\n| Attribute<\/th>\n | As described in approved labelling<\/th>\n<\/tr>\n<\/thead>\n | \n\n| Approved indications (US)<\/td>\n | Erectile dysfunction; signs and symptoms of BPH; pulmonary arterial hypertension<\/td>\n<\/tr>\n | \n| Dosing patterns<\/td>\n | As-needed or once-daily regimens, depending on indication and approved labelling<\/td>\n<\/tr>\n | \n| Common tablet strengths<\/td>\n | 2.5, 5, 10, 20 mg<\/td>\n<\/tr>\n | \n| Terminal half-life<\/td>\n | Approximately 17.5 hours in healthy subjects<\/td>\n<\/tr>\n | \n| Metabolism<\/td>\n | Predominantly hepatic via CYP3A4<\/td>\n<\/tr>\n | \n| Food effect<\/td>\n | Rate and extent of absorption not influenced by food<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n Provided for orientation only, drawn from approved labelling. Dosing decisions belong to a prescribing clinician. [Source: EMA Summary of Product Characteristics, Cialis; FDA Prescribing Information, Cialis]<\/p>\n \n Who should not take tadalafil<\/p>\n \n- Anyone using any form of organic nitrate. Clinical studies indicate tadalafil augments the hypotensive effects of nitrates, and co-administration is contraindicated. [Source: EMA Summary of Product Characteristics, Cialis]<\/li>\n
- Anyone with known hypersensitivity to tadalafil or any excipient in the formulation.<\/li>\n
- Caution applies with alpha-blockers and other antihypertensives because of additive blood-pressure effects, and in patients for whom sexual activity is inadvisable on cardiovascular grounds.<\/li>\n
- Caution applies in patients predisposed to priapism, such as those with sickle cell anaemia, multiple myeloma or leukaemia, or with anatomical deformation of the penis. [Source: Health Canada Product Monograph, CIALIS]<\/li>\n<\/ul>\n
Labelled warnings include prolonged erection and priapism, sudden decrease or loss of vision associated with non-arteritic anterior ischaemic optic neuropathy, and sudden decrease or loss of hearing. Product labelling in some jurisdictions contraindicates use in patients with a previous episode of NAION. The product carries no boxed warning in the US. [Source: FDA Prescribing Information, Cialis; Health Canada Product Monograph, CIALIS]<\/p>\n<\/div>\n When to see a doctor<\/h3>\nAnyone taking tadalafil who experiences an erection lasting more than four hours, sudden vision or hearing changes, chest pain, fainting, or signs of an allergic reaction should seek medical attention promptly. Tadalafil is a prescription medicine and should be taken only under the supervision of a licensed clinician.<\/p>\n \n A note on unapproved products.<\/strong> Tadalafil sold without a prescription, through unlicensed online channels, or marketed as a “natural” or herbal alternative sits outside the regulated supply chain. Products sold as botanical or dietary supplements have repeatedly been found to contain undeclared PDE5 inhibitors, which creates a real interaction risk for anyone taking nitrates and offers no assurance of identity, strength or purity. This site supplies pharmaceutical-grade API to qualified business buyers only and does not sell to individuals or supply finished medicines to consumers.<\/p>\n<\/div>\nFrequently asked questions<\/h2>\n\nIs a CEP valid in the United States?<\/summary>\nNot as a substitute for US regulatory support. A CEP is issued by EDQM and supports European filings. A US application referencing an outside API source normally relies on a Type II Drug Master File referenced under a Letter of Authorization. Many tadalafil manufacturers hold both, but they are not interchangeable.<\/p>\n<\/details>\n\nHow long is a CEP valid?<\/summary>\nA CEP must be renewed once, five years after the issue date of the original certificate, for it to remain valid, regardless of any revisions made in the interim. Holders must also notify EDQM of changes and keep the application aligned with the current Ph. Eur. monograph.<\/p>\n<\/details>\n\nWhat is the difference between a CEP and an ASMF?<\/summary>\nBoth support the quality section of a European application. A CEP is assessed once by EDQM and can then be referenced across applications. An ASMF is submitted with open and restricted parts and assessed within each application by the relevant authority. Which route a supplier has taken affects your filing timeline.<\/p>\n<\/details>\n\nCan a CEP be suspended or withdrawn?<\/summary>\nYes. EDQM maintains a published policy on suspension or cancellation of certificates of suitability. This is the main reason to check the EDQM database rather than relying on a PDF a supplier sent you, which reflects only the day it was issued.<\/p>\n<\/details>\n\nSafety: why does the nitrate contraindication matter when qualifying an API source?<\/summary>\nBecause it sets the stakes. Clinical studies indicate tadalafil augments the hypotensive effects of nitrates, and co-administration is contraindicated. That is why the molecule is prescription-only, why identity and strength control at the drug substance stage is not a paperwork exercise, and why undeclared tadalafil in supplements marketed as natural is a genuine public health issue rather than a labelling technicality. [Source: EMA Summary of Product Characteristics, Cialis]<\/p>\n Sources<\/h2>\n\n- EDQM. Certification Policy Documents and Guidelines, including PA\/PH\/CEP (08) 17 on suspension or cancellation and PA\/PH\/CEP (21) 57 on CEP holder responsibilities.<\/li>\n
- EDQM. Notifications, Revisions, Renewals and Sister Files.<\/li>\n
- EDQM. Guideline on requirements for revision and renewal of certificates of suitability, PA\/PH\/CEP (04) 02.<\/li>\n
- EDQM. Implementation of the European Pharmacopoeia, notifications for CEP holders.<\/li>\n
- Resolution AP-CSP (07) 1 on Certification of Suitability to the Monographs of the European Pharmacopoeia.<\/li>\n
- Health Products Regulatory Authority (Ireland). Public Assessment Report, tadalafil film-coated tablets, 2024.<\/li>\n
- European Medicines Agency. Summary of Product Characteristics, Cialis.<\/li>\n
- US FDA. Prescribing Information, Cialis and Adcirca.<\/li>\n
- Health Canada. Product Monograph, CIALIS.<\/li>\n<\/ol>\n
\n This article is for informational purposes only and is not a substitute for professional medical advice. Consult your doctor before starting, stopping, or changing any medication. Regulatory information is provided for general guidance and does not constitute regulatory or legal advice. Verify certification status and filing requirements against current EDQM and national authority sources before acting.<\/p>\n B2B supply only. We do not sell prescription medicines to individuals.<\/p>\n<\/div>\n<\/details>\n","protected":false},"excerpt":{"rendered":" Direct answer A CEP-certified tadalafil API suppliers holds a Certificate of Suitability issued by EDQM, confirming that its tadalafil can be adequately controlled by the European Pharmacopoeia monograph. A CEP supports European marketing authorisation filings. It is not a US credential, does not replace a Drug Master File, and should be verified in the EDQM […]<\/p>\n","protected":false},"author":1,"featured_media":262,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"pb_authors":"[{\"role\":\"Written by\",\"name\":\"Dr Arnika Sharma\",\"credentials\":\"MBBS, MD (Medicine)\",\"linkedin\":\"https:\\\/\\\/www.linkedin.com\\\/in\\\/dr-arnika-sharma-31a183245\\\/\",\"bio\":\"Medical Science Liaison with a strong passion for advancing scientific exchange and improving patient outcomes through evidence-based communication. Experienced in building trusted relationships with healthcare professionals, key opinion leaders (KOLs), and cross-functional teams to support the responsible use of innovative therapies.\"}]","pb_last_updated":"","pb_uses_pdg":false,"footnotes":""},"categories":[3],"tags":[],"class_list":["post-261","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-guide"],"_links":{"self":[{"href":"https:\/\/tadalafil-seller.com\/blog\/wp-json\/wp\/v2\/posts\/261","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tadalafil-seller.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tadalafil-seller.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tadalafil-seller.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/tadalafil-seller.com\/blog\/wp-json\/wp\/v2\/comments?post=261"}],"version-history":[{"count":1,"href":"https:\/\/tadalafil-seller.com\/blog\/wp-json\/wp\/v2\/posts\/261\/revisions"}],"predecessor-version":[{"id":265,"href":"https:\/\/tadalafil-seller.com\/blog\/wp-json\/wp\/v2\/posts\/261\/revisions\/265"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tadalafil-seller.com\/blog\/wp-json\/wp\/v2\/media\/262"}],"wp:attachment":[{"href":"https:\/\/tadalafil-seller.com\/blog\/wp-json\/wp\/v2\/media?parent=261"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tadalafil-seller.com\/blog\/wp-json\/wp\/v2\/categories?post=261"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tadalafil-seller.com\/blog\/wp-json\/wp\/v2\/tags?post=261"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}} | | | | | | | | | | | | | | |